2023
Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies
Patel M, Donnellan W, Byrne M, Asch A, Zeidan A, Baer M, Fathi A, Kuykendall A, Zheng F, Walker C, Cheng L, Marando C, Savona M. Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies. Clinical Lymphoma Myeloma & Leukemia 2023, 23: 674-686. PMID: 37290996, DOI: 10.1016/j.clml.2023.05.002.Peer-Reviewed Original ResearchConceptsTreatment-emergent adverse eventsDose-limiting toxicityAdvanced hematologic malignanciesAcute myeloid leukemiaMyelodysplastic syndromeHematologic malignanciesCare agentsHigh-risk myelodysplastic syndromeMDS/myeloproliferative neoplasmPhase 1/2 studyEffective combination strategiesAdverse eventsComplete responseLymphoproliferative neoplasmsWeek 12Multiple myelomaSpleen volumeAcute leukemiaMyeloid leukemiaPreclinical modelsPatientsMyeloproliferative neoplasmsMoloney murine leukemia virus (PIM) kinasesMyelofibrosisKinase inhibitorsCurrent landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)
Bewersdorf J, Xie Z, Bejar R, Borate U, Boultwood J, Brunner A, Buckstein R, Carraway H, Churpek J, Daver N, Porta M, DeZern A, Fenaux P, Figueroa M, Gore S, Griffiths E, Halene S, Hasserjian R, Hourigan C, Kim T, Komrokji R, Kuchroo V, List A, Loghavi S, Majeti R, Odenike O, Patnaik M, Platzbecker U, Roboz G, Sallman D, Santini V, Sanz G, Sekeres M, Stahl M, Starczynowski D, Steensma D, Taylor J, Abdel-Wahab O, Xu M, Savona M, Wei A, Zeidan A. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS). Blood Reviews 2023, 60: 101072. PMID: 36934059, DOI: 10.1016/j.blre.2023.101072.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsImmune checkpoint inhibitorsSpecific molecular alterationsNovel animal modelInnate immune systemCheckpoint inhibitorsImmune dysregulationMDS patientsClinical trialsNovel therapiesTherapeutic strategiesAnimal modelsGermline predispositionImmune systemMolecular alterationsClinical researchInternational ConsortiumNeoplasmsClinical workGenetic landscapeInternational WorkshopPatientsCurrent landscapePathogenesisTherapyDisease
2022
Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes
Zeidan AM, DeAngelo DJ, Palmer J, Seet CS, Tallman MS, Wei X, Raymon H, Sriraman P, Kopytek S, Bewersdorf JP, Burgess MR, Hege K, Stock W. Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes. Annals Of Hematology 2022, 101: 557-569. PMID: 34981142, PMCID: PMC9414073, DOI: 10.1007/s00277-021-04734-2.Peer-Reviewed Original ResearchConceptsAnti-drug antibodiesAcute myeloid leukemiaDose-limiting toxicityRefractory acute myeloid leukemiaHigh-risk myelodysplastic syndromeMyelodysplastic syndromeMyeloid leukemiaCommon treatment-emergent adverse eventsTreatment-emergent adverse eventsADA-positive patientsPhase 2 dosePresence/frequencyUnexpected safety findingsPhase 1 studyAnti-CD47 antibodyCD47-SIRPα interactionMacrophage-mediated killingHematological cancer cell linesFebrile neutropeniaMonotherapy activityCancer cell linesPrimary endpointSecondary endpointsAdverse eventsObjective response
2018
Aplastic anemia: Etiology, molecular pathogenesis, and emerging concepts
Shallis RM, Ahmad R, Zeidan AM. Aplastic anemia: Etiology, molecular pathogenesis, and emerging concepts. European Journal Of Haematology 2018, 101: 711-720. PMID: 30055055, DOI: 10.1111/ejh.13153.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAplastic anemiaMolecular pathogenesisDevelopment of AAStem cell injuryHematopoietic stem cell injuryT cell homeostasisTelomerase complex genesBone marrow failureLikely autoimmuneMarrow featuresPeripheral cytopeniasPathologic featuresPatient outcomesMonosomy 7Rare disorderAA pathogenesisCell injuryPathogenic mechanismsTrisomy 8Clonal diseaseCytogenetic abnormalitiesPathogenesisMarrow failureDiseaseUniparental disomy
2017
Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment
Gbolahan OB, Zeidan AM, Stahl M, Abu Zaid M, Farag S, Paczesny S, Konig H. Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment. International Journal Of Molecular Sciences 2017, 18: 1660. PMID: 28758974, PMCID: PMC5578050, DOI: 10.3390/ijms18081660.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsLeukemic microenvironmentAllogeneic stem cell transplantationLong-term disease controlAcute myeloid leukemia (AML) treatmentMonoclonal antibodiesIntensive chemotherapeutic protocolsImmune-based therapiesMajority of patientsOverall survival rateStem cell transplantationManagement of AMLAcute myeloid leukemiaElicit immune responsesMyeloid leukemia treatmentEarly phase studiesNovel treatment conceptsImmunotherapeutic interventionsMost patientsAML therapyImmunotherapeutic conceptsPoor outcomeCell transplantationToxic therapiesChemotherapeutic protocolsMyeloid leukemiaThe skin as a window to the blood: Cutaneous manifestations of myeloid malignancies
Li AW, Yin ES, Stahl M, Kim TK, Panse G, Zeidan AM, Leventhal JS. The skin as a window to the blood: Cutaneous manifestations of myeloid malignancies. Blood Reviews 2017, 31: 370-388. PMID: 28732587, DOI: 10.1016/j.blre.2017.07.003.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCutaneous manifestationsMyeloid malignanciesMyeloid diseasesCommon cutaneous manifestationStage of diseaseHematologists/oncologistsSignificant clinical implicationsMalignant hematopoietic cellsCutaneous involvementSkin manifestationsTargeted agentsSkin findingsClinical reviewCutaneous reactionsDermatologic findingsPrognostic valueImmune statusDiagnostic challengeEarly recognitionHematologic malignanciesMalignancyClinical implicationsDiseaseManifestationsHematopoietic cells
2016
Emerging biological therapies for the treatment of myelodysplastic syndromes
Zeidan AM, Stahl M, Komrokji R. Emerging biological therapies for the treatment of myelodysplastic syndromes. Expert Opinion On Emerging Drugs 2016, 21: 283-300. PMID: 27486848, DOI: 10.1080/14728214.2016.1220534.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMyelodysplastic syndromeHistone deacetylase inhibitorsTreatment optionsNovel agentsLower-risk myelodysplastic syndromesHigh-risk myelodysplastic syndromeHMA treatment failureRisk-adaptive therapySignificant clinical activityNovel treatment optionsNovel effective therapiesNovel therapeutic approachesHMA failureBiological therapyTreatment failureBone marrow nicheClinical trialsEffective therapyClinical activityImmune responseTherapeutic approachesSurvival advantageFuture therapiesImmune systemDeacetylase inhibitors
2015
Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions
Kim TK, Gore SD, Zeidan AM. Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions. Seminars In Hematology 2015, 52: 172-183. PMID: 26111464, PMCID: PMC5785931, DOI: 10.1053/j.seminhematol.2015.04.003.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcute myeloid leukemiaMyeloid leukemiaTreatment of AMLPathogenesis of AMLDevelopment of AMLNormal physiologic developmentHistone deacetylase inhibitorsEpigenetic therapyDNA methylationHistone methylation/acetylationTherapeutic optionsClinical evaluationDNA methyltransferase inhibitorHistone tail modificationsInhibitor of histoneMethylation/acetylationPromising drugClinical practiceTherapeutic targetingMutant isocitrate dehydrogenasesDeacetylase inhibitorsActual DNA sequenceAberrant DNA methylationPhysiologic developmentImportant mechanismGenome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy?
Lee EJ, Zeidan AM. Genome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy? Expert Review Of Hematology 2015, 8: 155-158. PMID: 25697572, DOI: 10.1586/17474086.2015.1016905.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMyelodysplastic syndromeHigh-risk myelodysplastic syndromeMolecular mutationsRecurrent molecular mutationsReliable clinical predictorsIndependent prognostic valueMyelodysplastic syndrome patientsUrgent clinical needIdentification of biomarkersAgent therapyClinical predictorsPrognostic valuePrognostic subgroupsSyndrome patientsVariable coursePatientsClinical implicationsTET2 mutationsClinical needSyndromeTherapyRecurrent mutationsBiomarkersHMAsResearch priorities